StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) income statement

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.43−0.02 (-3.39%)

Close on Nov 18, 2026Market cap $249.06KP/E –Yield –

Virax Biolabs Group Ltd income statement

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin
61.9%
Operating margin
-51515.2%
Net margin
-40439.1%
Return on equity, FY2026
-75.7%

Financial strength

Current ratio
9.97
Debt to equity
–
Debt to assets
–
Cash to current liabilities
940.0%

Valuation

P/E ratio
–
Price to sales
20.05
Price to book
0.03
Dividend yield
–

See a number that looks wrong?